Drug Trial Radar · NCT07894211
QLC5508 vs. Investigator's Choice Chemotherapy in Advanced Extrapulmonary Neuroendocrine Carcinoma
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Oct 26, 2026
Primary completion
Mar 26, 2029
Study completion Jun 30, 2030
Sponsor
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is a Phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of QLC5508 versus investigator's choice chemotherapy in participants with advanced EP-NEC that has failed after at least one prior platinum-based chemotherapy regimen.
Conditions
- Extrapulmonary Neuroendocrine Carcinoma
Interventions
Investigator's Choice Chemotherapy (FOLFIRI or FOLFOX regimen)Drug
FOLFIRI regimen: Irinotecan 180 mg/m² intravenous infusion on Day 1 and Day 15, leucovorin 400 mg/m² intravenous infusion on Day 1 and Day 15, and fluorouracil 400 mg/m² intravenous push on Day 1 and Day 15, followed by fluorouracil 2400 mg/m² via continuous intravenous infusion over 46-48 hours, once every 2 weeks. Each treatment cycle is 4 weeks. FOLFOX regimen: oxaliplatin 85 mg/m² intravenous infusion on Day 1 and Day 15, leucovorin 400 mg/m² intravenous infusion on Day 1 and Day 15, and fluorouracil 400 mg/m² intravenous push on Day 1 and Day 15, followed by fluorouracil 2400 mg/m² via continuous intravenous infusion over 46-48 hours, once every 2 weeks. Each treatment cycle is 4 weeks.
QLC5508Drug
QLC5508 will be administered intravenously once every 2 weeks. Each treatment cycle is 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to approximately 48 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.